Fjarde AP Fonden Fourth Swedish National Pension Fund Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in United Therapeutics Co. (NASDAQ:UTHR) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,300 shares of the biotechnology company’s stock after buying an additional 1,900 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund owned 0.05% of United Therapeutics worth $8,221,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics in the fourth quarter valued at about $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics in the 3rd quarter worth about $33,000. Capital Performance Advisors LLP purchased a new position in shares of United Therapeutics in the third quarter worth about $82,000. MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in shares of United Therapeutics during the third quarter worth $111,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on UTHR shares. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Down 0.8 %

Shares of UTHR opened at $358.21 on Tuesday. The stock has a market capitalization of $15.99 billion, a P/E ratio of 15.73, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The firm has a fifty day simple moving average of $362.39 and a two-hundred day simple moving average of $360.91.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $932,745.15. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 114,164 shares of company stock valued at $41,671,293. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.